Borgonovo K - Search Results

1

Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies.

Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Petrelli F, et al. Among authors: borgonovo k. Expert Rev Anticancer Ther. 2012 Oct;12(10):1299-312. doi: 10.1586/era.12.110. Expert Rev Anticancer Ther. 2012. PMID: 23176618 Review.

2

Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.

Garassino MC, Borgonovo K, Rossi A, Mancuso A, Martelli O, Tinazzi A, Di Cosimo S, La Verde N, Sburlati P, Bianchi C, Farina G, Torri V. Garassino MC, et al. Among authors: borgonovo k. Anticancer Res. 2009 Jul;29(7):2691-701. Anticancer Res. 2009. PMID: 19596948 Free article. Review.

3

What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies.

Petrelli F, Borgonovo K, Ghilardi M, Cabiddu M, Barni S. Petrelli F, et al. Among authors: borgonovo k. Rev Recent Clin Trials. 2010 Jan;5(1):43-56. doi: 10.2174/157488710790820553. Rev Recent Clin Trials. 2010. PMID: 20205687 Review.

4

Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey.

Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM). Roila F, et al. Among authors: borgonovo k. Tumori. 2009 Nov-Dec;95(6):647-51. doi: 10.1177/030089160909500601. Tumori. 2009. PMID: 20210223

5

Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.

Petrelli F, Borgonovo K, Barni S. Petrelli F, et al. Among authors: borgonovo k. Expert Opin Pharmacother. 2010 Jun;11(8):1413-32. doi: 10.1517/14656561003796562. Expert Opin Pharmacother. 2010. PMID: 20446855 Review.

6

Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials.

Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Petrelli F, et al. Among authors: borgonovo k. Anticancer Drugs. 2011 Feb;22(2):128-35. doi: 10.1097/cad.0b013e32834120aa. Anticancer Drugs. 2011. PMID: 21218604 Review.

7

Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis.

Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Petrelli F, et al. Among authors: borgonovo k. Int J Colorectal Dis. 2011 Jul;26(7):823-33. doi: 10.1007/s00384-011-1149-0. Epub 2011 Feb 1. Int J Colorectal Dis. 2011. PMID: 21286919

8

Targeted therapies and other agents as first-line maintenance and beyond: particular benefit in pulmonary adenocarcinoma patients.

Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Petrelli F, et al. Among authors: borgonovo k. Curr Med Chem. 2011;18(11):1640-50. doi: 10.2174/092986711795471310. Curr Med Chem. 2011. PMID: 21428883

9

Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies.

Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Petrelli F, et al. Among authors: borgonovo k. Expert Opin Drug Saf. 2012 May;11 Suppl 1:S9-19. doi: 10.1517/14740338.2011.606213. Epub 2011 Aug 16. Expert Opin Drug Saf. 2012. PMID: 21843103 Review.

10

The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature.

Petrelli F, Borgonovo K, Barni S. Petrelli F, et al. Among authors: borgonovo k. Eur J Surg Oncol. 2011 Oct;37(10):836-47. doi: 10.1016/j.ejso.2011.07.008. Epub 2011 Aug 16. Eur J Surg Oncol. 2011. PMID: 21843922 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters